SMT201500245B - Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso - Google Patents

Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso

Info

Publication number
SMT201500245B
SMT201500245B SM201500245T SM201500245T SMT201500245B SM T201500245 B SMT201500245 B SM T201500245B SM 201500245 T SM201500245 T SM 201500245T SM 201500245 T SM201500245 T SM 201500245T SM T201500245 B SMT201500245 B SM T201500245B
Authority
SM
San Marino
Prior art keywords
irinotecan
liposome
preparation process
respective hydrochloride
hydrochloride
Prior art date
Application number
SM201500245T
Other languages
English (en)
Italian (it)
Inventor
Xinyong Tong
Guofeng Lei
Chengxia Yu
Liang Chen
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai Hengrui Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai Hengrui Pharm Co Ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of SMT201500245B publication Critical patent/SMT201500245B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
SM201500245T 2009-12-03 2015-10-09 Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso SMT201500245B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2009/075298 WO2011066684A1 (zh) 2009-12-03 2009-12-03 伊立替康或盐酸伊立替康脂质体及其制备方法

Publications (1)

Publication Number Publication Date
SMT201500245B true SMT201500245B (it) 2015-10-30

Family

ID=44114598

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500245T SMT201500245B (it) 2009-12-03 2015-10-09 Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso

Country Status (22)

Country Link
US (2) US20120282325A1 (xx)
EP (1) EP2508170B1 (xx)
JP (1) JP5645954B2 (xx)
KR (2) KR101780915B1 (xx)
CN (1) CN102271659B (xx)
AU (1) AU2009356132B2 (xx)
BR (1) BR112012012151B8 (xx)
CA (1) CA2782911C (xx)
CY (1) CY1116811T1 (xx)
DK (1) DK2508170T3 (xx)
ES (1) ES2547698T3 (xx)
HK (1) HK1159482A1 (xx)
HR (1) HRP20150911T1 (xx)
HU (1) HUE027467T2 (xx)
MX (1) MX2012005775A (xx)
PL (1) PL2508170T3 (xx)
PT (1) PT2508170E (xx)
RU (1) RU2526114C2 (xx)
SI (1) SI2508170T1 (xx)
SM (1) SMT201500245B (xx)
WO (1) WO2011066684A1 (xx)
ZA (1) ZA201203316B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102935066B (zh) * 2011-08-16 2014-09-17 齐鲁制药有限公司 一种伊立替康脂质体制剂及其制备方法
PT2768484T (pt) 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
JP6426600B2 (ja) * 2012-04-10 2018-11-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ビス−ポリマー脂質−ペプチド複合体及びそのナノ粒子
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
CN102697720B (zh) * 2012-06-29 2014-01-15 海南灵康制药有限公司 盐酸伊立替康脂质纳米粒注射剂
CN103181898B (zh) * 2012-11-23 2016-03-09 杭州师范大学 一种奥沙利铂脂质体及其应用
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
PT3138555T (pt) 2014-04-30 2020-12-15 Fujifilm Corp Composição lipossómica e método de produção da mesma
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
CN108495629A (zh) 2015-08-21 2018-09-04 益普生生物制药有限公司 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法
WO2017066726A1 (en) 2015-10-16 2017-04-20 Merrimack Pharmaceuticals, Inc. Stabilizing camptothecin pharmaceutical compositions
CN107281102A (zh) * 2016-04-11 2017-10-24 江苏竞诺择生物医药科技有限公司 一种用于结直肠肿瘤治疗的药物微粒组合物
CN107456456A (zh) * 2016-06-03 2017-12-12 江苏恒瑞医药股份有限公司 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途
US20170368082A1 (en) * 2016-06-28 2017-12-28 Chimerix, Inc. Formulations of brincidofovir
CN106109415B (zh) * 2016-07-26 2019-01-29 金华市人民医院 一种载喜树碱类抗肿瘤药物脂质体、制备方法及其应用
AU2017324718B2 (en) 2016-09-09 2022-09-29 Irisys, Inc. Lipsomal anticancer compositions
KR102653436B1 (ko) * 2016-10-28 2024-03-29 르 라보레또레 쎄르비에르 암의 치료에서 사용하기 위한 리포솜 제형
MA46709A (fr) * 2016-11-02 2019-09-11 Ipsen Biopharm Ltd Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
US10722465B1 (en) * 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
CN109675047B (zh) * 2019-01-07 2020-12-04 中国科学院化学研究所 一种对具有游离羟基的化合物进行脂质体修饰的方法
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US11273124B2 (en) * 2019-05-23 2022-03-15 Brown University Antifungal nanoparticles for targeted treatment of fungal infections
CN114177278A (zh) * 2021-10-18 2022-03-15 山东多美康生物医药有限公司 脂质体制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
EP1121102B1 (en) * 1998-09-16 2003-04-23 Alza Corporation Liposome-entrapped topoisomerase inhibitors
EP1443900B1 (en) * 2001-11-13 2012-05-23 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
EP1746976B1 (en) * 2004-05-03 2017-01-11 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
UA85099C2 (xx) * 2004-06-01 2008-12-25 Кабусики Кайся Якулт Хонса Ліпосомальний склад з іринотеканом$липосомный состав с иринотеканом
CN1326525C (zh) * 2004-11-26 2007-07-18 复旦大学 10－羟基喜树碱长循环脂质体及其冻干制剂
WO2007076117A2 (en) * 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
US7489990B2 (en) * 2006-07-17 2009-02-10 Fehr Stephen L Systems and methods for calculating and predicting near term production cost, incremental heat rate, capacity and emissions of electric generation power plants based on current operating and, optionally, atmospheric conditions
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
CN101019834A (zh) * 2006-12-31 2007-08-22 西安力邦医药科技有限责任公司 注射用7－乙基－10羟基喜树碱脂质体的制备方法
CA2681302C (en) 2007-03-19 2013-07-23 Dhiraj Khattar Proliposomal and liposomal compositions of poorly water-soluble compounds
CN101283983A (zh) * 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物

Also Published As

Publication number Publication date
KR20160140992A (ko) 2016-12-07
MX2012005775A (es) 2012-06-13
US10022365B2 (en) 2018-07-17
ES2547698T3 (es) 2015-10-08
AU2009356132B2 (en) 2015-01-22
BR112012012151B1 (pt) 2021-01-19
KR101780915B1 (ko) 2017-09-21
JP2013512262A (ja) 2013-04-11
WO2011066684A1 (zh) 2011-06-09
DK2508170T3 (en) 2015-09-21
HUE027467T2 (en) 2016-10-28
EP2508170B1 (en) 2015-07-29
AU2009356132A1 (en) 2012-06-21
CA2782911A1 (en) 2011-06-09
EP2508170A4 (en) 2014-01-15
PT2508170E (pt) 2015-10-16
BR112012012151B8 (pt) 2021-05-25
CN102271659B (zh) 2013-09-18
ZA201203316B (en) 2013-11-27
US20170189392A1 (en) 2017-07-06
PL2508170T3 (pl) 2015-12-31
JP5645954B2 (ja) 2014-12-24
US20120282325A1 (en) 2012-11-08
KR20120089754A (ko) 2012-08-13
EP2508170A1 (en) 2012-10-10
CN102271659A (zh) 2011-12-07
HRP20150911T1 (hr) 2015-10-23
RU2526114C2 (ru) 2014-08-20
RU2012123875A (ru) 2014-01-20
CA2782911C (en) 2016-08-23
SI2508170T1 (sl) 2015-12-31
BR112012012151A2 (pt) 2016-04-12
HK1159482A1 (en) 2012-08-03
CY1116811T1 (el) 2017-03-15

Similar Documents

Publication Publication Date Title
SMT201500245B (it) Liposoma di irinotecan o rispettivo cloridrato e procedimento di preparazione dello stesso
GB2471765B (en) Geopolymeric structural building units and methods of manufacture thereof
DK2419670T3 (da) Leveringsmetode og sammensætninger
EP2603201A4 (en) LIPOSOME COMPOSITIONS AND USE METHOD THEREFOR
EP2470485A4 (en) CERAMIC ISOLATOR AND METHODS OF USE AND MANUFACTURE
IL232598A0 (en) Crystalline forms of vilzodone and vilzodone hydrochloride
EP2462152A4 (en) COMPOSITION AND METHODS FOR TREATING VIRAL INFECTIONS AND TUMORS OF VIRAL ORIGIN
BRPI0819704A2 (pt) Branqueador líquido estável em prateleira e processo de preparação deste
DK2415800T3 (da) Hyperforgrenet polyoxyalkylenforbindelse og fremgangsmåde til deres fremstilling
IL197655A0 (en) Emulsions and methods of their production
BR112014002804A2 (pt) revestimento e método de preparação do mesmo
CU24148B1 (es) Intermedios de agomelatina y método de preparación de éstos
EP2656849A4 (en) LIPOSOME COMPRISING A COMBINATION OF CHLOROQUINE AND ADRIAMYCIN AND PREPARATION METHOD THEREOF
FI20105638A0 (fi) Kivipinnoitteen valmistus
FI20095464A (fi) Puhdistusmenetelmä ja puhdistuslaite
IT1397894B1 (it) Dispositivo micromeccanico e procedimento per la produzione dello stesso
EP2342356A4 (en) AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF
IT1394217B1 (it) Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
IT1403286B1 (it) Procedimento per la preparazione di compresse comprendenti 5-idrossitriptofano e triptofano
FI20105739A0 (fi) Kivestä koostuva kaiutinkotelo ja sen valmistusmenetelmä
IL219316A0 (en) Processes for the preparation of 5-lipooxygenase activating protein inhibitors and their intermediates
EP2467375A4 (en) FORMS OF DEXLANDSOPRAZOLE AND METHOD OF MANUFACTURING THEREOF
BR112012015233A2 (pt) "processo de preparação de composto farmacêuticos e compostos intermediarios
TH144556B (th) แอนติ-cd79b แอนติบอดีและอิมมูโนคอนจูเกตและวิธีการใช้งาน
TH85281B (th) Tigecycline and methods of preparation